Virological and Serological Assessment of US Army Trainees Isolated for Coronavirus Disease 2019.
Army recruit
SARS-CoV-2
cycle threshold value
isolation
sgRNA
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
11 11 2022
11 11 2022
Historique:
received:
13
02
2022
accepted:
09
05
2022
pubmed:
12
5
2022
medline:
15
11
2022
entrez:
11
5
2022
Statut:
ppublish
Résumé
Laboratory screening for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key mitigation measure to avoid the spread of infection among recruits starting basic combat training in a congregate setting. Because viral nucleic acid can be detected persistently after recovery, we evaluated other laboratory markers to distinguish recruits who could proceed with training from those who were infected. Recruits isolated for coronavirus disease 2019 (COVID-19) were serially tested for SARS-CoV-2 subgenomic ribonucleic acid (sgRNA), and viral load (VL) by reverse-transcriptase polymerase chain reaction (RT-PCR), and for anti- SARS-CoV-2. Cluster and quadratic discriminant analyses of results were performed. Among 229 recruits isolated for COVID-19, those with a RT-PCR cycle threshold >30.49 (sensitivity 95%, specificity 96%) or having sgRNA log10 RNA copies/mL <3.09 (sensitivity and specificity 96%) at entry into isolation were likely SARS-CoV-2 uninfected. Viral load >4.58 log10 RNA copies/mL or anti-SARS-CoV-2 signal-to-cutoff ratio <1.38 (VL: sensitivity and specificity 93%; anti-SARS-CoV-2: sensitivity 83%, specificity 79%) had comparatively lower sensitivity and specificity when used alone for discrimination of infected from uninfected. Orthogonal laboratory assays used in combination with RT-PCR may have utility in determining SARS-CoV-2 infection status for decisions regarding isolation.
Sections du résumé
BACKGROUND
Laboratory screening for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key mitigation measure to avoid the spread of infection among recruits starting basic combat training in a congregate setting. Because viral nucleic acid can be detected persistently after recovery, we evaluated other laboratory markers to distinguish recruits who could proceed with training from those who were infected.
METHODS
Recruits isolated for coronavirus disease 2019 (COVID-19) were serially tested for SARS-CoV-2 subgenomic ribonucleic acid (sgRNA), and viral load (VL) by reverse-transcriptase polymerase chain reaction (RT-PCR), and for anti- SARS-CoV-2. Cluster and quadratic discriminant analyses of results were performed.
RESULTS
Among 229 recruits isolated for COVID-19, those with a RT-PCR cycle threshold >30.49 (sensitivity 95%, specificity 96%) or having sgRNA log10 RNA copies/mL <3.09 (sensitivity and specificity 96%) at entry into isolation were likely SARS-CoV-2 uninfected. Viral load >4.58 log10 RNA copies/mL or anti-SARS-CoV-2 signal-to-cutoff ratio <1.38 (VL: sensitivity and specificity 93%; anti-SARS-CoV-2: sensitivity 83%, specificity 79%) had comparatively lower sensitivity and specificity when used alone for discrimination of infected from uninfected.
CONCLUSIONS
Orthogonal laboratory assays used in combination with RT-PCR may have utility in determining SARS-CoV-2 infection status for decisions regarding isolation.
Identifiants
pubmed: 35543272
pii: 6583560
doi: 10.1093/infdis/jiac198
pmc: PMC9129211
doi:
Substances chimiques
RNA
63231-63-0
RNA, Viral
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1743-1752Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest . All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
Références
MMWR Morb Mortal Wkly Rep. 2020 Oct 02;69(39):1416-1418
pubmed: 33001871
Open Forum Infect Dis. 2021 Jun 11;8(7):ofab310
pubmed: 34295944
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
Cochrane Database Syst Rev. 2021 Mar 24;3:CD013705
pubmed: 33760236
J Infect Dis. 2021 Oct 28;224(8):1325-1332
pubmed: 34329473
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666
pubmed: 32442256
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):13-25
pubmed: 33113040
EBioMedicine. 2021 Jul;69:103455
pubmed: 34186490
Clin Infect Dis. 2021 Nov 2;73(9):e2952-e2959
pubmed: 33098412
BMC Med. 2021 Mar 15;19(1):77
pubmed: 33715626
JAMA Intern Med. 2020 Sep 1;180(9):1156-1163
pubmed: 32356867
Emerg Infect Dis. 2020 Nov;26(11):2701-2704
pubmed: 32749957
Microbiol Spectr. 2021 Dec 22;9(3):e0100321
pubmed: 34756092
Sci Adv. 2021 Jan 1;7(1):
pubmed: 33219112
Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):
pubmed: 34470866
EBioMedicine. 2020 Sep;59:102960
pubmed: 32853988
J Infect Dis. 2021 Oct 28;224(8):1287-1293
pubmed: 33870434
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
BMC Infect Dis. 2021 Oct 18;21(1):1071
pubmed: 34663212
PLoS Biol. 2021 Jul 12;19(7):e3001333
pubmed: 34252080
BMJ. 2021 Jul 6;374:n1637
pubmed: 34230058
Genome Res. 2021 Apr;31(4):645-658
pubmed: 33722935
Open Forum Infect Dis. 2021 Jul 29;8(9):ofab407
pubmed: 34514020
JAMA Netw Open. 2020 Jul 1;3(7):e2016818
pubmed: 32735339
J Clin Microbiol. 2022 Jan 19;60(1):e0160921
pubmed: 34669457
Clin Microbiol Infect. 2022 Jan;28(1):101-106
pubmed: 34400343
Clin Infect Dis. 2021 Sep 15;73(6):e1348-e1355
pubmed: 33846714
MMWR Morb Mortal Wkly Rep. 2021 Jan 08;70(1):14-19
pubmed: 33411699
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32518072